Tag: asthma therapeutics market size

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Asthma Therapeutics Market Set To Climb From $35.73 Billion In 2026 To $47.87 Billion By 2030

The asthma therapeutics market has experienced strong expansion in recent years. It is anticipated to increase from $33.11 billion in 2025 to $35.73 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. The market’s past growth can be attributed to the limited accessibility of biologics, the widespread use of short-acting beta agonists, the increasing global incidence of asthma, a surge in hospital and specialty clinic visits, and the common adoption of oral and inhaled medications.

The asthma therapeutics market is projected to experience substantial expansion in the coming years, reaching a valuation of $47.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is driven by factors such as the emergence of new biologics and combined treatment approaches, the broader adoption of telemedicine and digital health surveillance, heightened public understanding of preventive care, improved access to healthcare services in developing regions, and increased funding for drug research and development. Key trends anticipated during this period encompass the increasing embrace of tailored asthma treatments, a surge in the use of inhalers and biologics, the proliferation of homecare and distant monitoring technologies, a rising inclination towards combination inhalers, and a stronger emphasis on asthma management for both pediatric and elderly patients.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Asthma Therapeutics Market Growth Drivers: What’s Behind The Acceleration?

The rising occurrence of asthma is anticipated to drive the expansion of the asthma therapeutics market in the future. Asthma is a chronic condition characterized by inflammation and swelling in the airways, leading to their constriction, which impedes air passage from the nose and mouth to the lungs. The growing incidence of asthma can be attributed to heightened levels of pollutants, which irritate the respiratory passages and elevate the likelihood of developing this illness. Asthma therapeutics are instrumental in managing the condition by regulating inflammation in the airways, alleviating symptoms, and averting asthma episodes. For example, data from the UK Parliament, a UK government institution, indicated that in May 2025, approximately 3,886,879 individuals over six years old had an asthma diagnosis in 2023-24, representing 6.5% of England’s population. Consequently, the expanding prevalence of asthma is a key factor propelling the growth of the asthma therapeutics market.

Asthma Therapeutics Market Segmentation And Category Overview

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

Asthma Therapeutics Market Trends: What’s Defining The Industry’s Next Phase?

Companies within the asthma therapeutics market are prioritizing the creation of advanced solutions, such as anti-inflammatory rescue inhalers, to improve symptom relief, manage inflammation, and enhance overall disease management. This type of rescue inhaler represents a dual-action therapeutic strategy, integrating a rapid-acting bronchodilator with an inhaled corticosteroid within a single device, which enables quick bronchodilation, immediate inflammation reduction when needed, and helps avert severe asthma attacks. As an illustration, in January 2024, the UK-based biopharmaceutical firm AstraZeneca plc introduced AIRSUPRA, an anti-inflammatory rescue inhaler that received FDA approval. It is designed to provide rapid symptom alleviation along with swift anti-inflammatory effects, offering dual-mechanism dosing as required, real-time suppression of airway inflammation, and assistance in preventing lung-function deterioration linked to exacerbations. AIRSUPRA contributes to better asthma control, lowers the likelihood of severe attacks, and enhances the overall efficacy of rescue therapies.

Asthma Therapeutics Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

View The Full Asthma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Asthma Therapeutics Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Asthma Therapeutics Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The asthma therapeutics sector has experienced robust expansion in recent years. Its projected growth is from $33.11 billion in 2025 to $35.73 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.9%. Historical market gains were driven by constrained access to biologics, a heavy dependence on short-acting beta agonists, the worldwide increase in asthma prevalence, a greater frequency of hospital and specialty clinic visits, and the growing use of both oral and inhaled treatments.

Over the coming years, the asthma therapeutics market is projected to experience robust expansion. By 2030, its value is anticipated to reach $47.87 billion, reflecting a compound annual growth rate (CAGR) of 7.6%. Several factors are expected to drive this growth during the forecast period, including the emergence of novel biologics and combination therapies, the expansion of telemedicine and digital health monitoring, greater awareness of preventive treatment, improved healthcare accessibility in emerging economies, and increased investment in research and drug development. Key trends shaping the market in the future encompass a growing preference for personalized asthma treatments, higher usage of inhalers and biologics, the broadening of homecare and remote monitoring services, an increased shift toward combination inhaler products, and a stronger emphasis on managing asthma in pediatric and geriatric populations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Asthma Therapeutics Market Development Factors: Which Trends Are Supporting Demand?

The rising incidence of asthma is anticipated to boost the expansion of the asthma therapeutics market in the future. Asthma is a chronic condition characterized by inflammation and swelling of the airways, which leads to their narrowing and hinders the transport of air from the nose and mouth to the lungs. This increase in asthma cases is largely attributed to growing levels of pollutants, which aggravate the airways and heighten the likelihood of developing the disorder. Asthma therapeutics are utilized to treat the condition by reducing airway inflammation, alleviating symptoms, and preventing attacks. For example, as reported by the UK Parliament, a government body in the United Kingdom, in May 2025, 3,886,879 people over the age of six were diagnosed with asthma in England during 2023-24, representing 6.5% of the population. Consequently, the escalating prevalence of asthma is fueling the growth of the asthma therapeutics market.

Asthma Therapeutics Market Segment Analysis And Revenue Opportunities

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

Asthma Therapeutics Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the asthma therapeutics market are concentrating on creating advanced therapies, including anti-inflammatory rescue inhalers, to improve symptom management, control inflammation, and optimize overall disease care. This type of inhaler represents a dual-action treatment that merges a rapid-acting bronchodilator with an inhaled corticosteroid within one device, offering fast airway widening, immediate reduction of inflammation on demand, and prevention of serious asthma episodes. A notable example is AstraZeneca plc, a UK-based biopharmaceutical firm, which debuted AIRSUPRA in January 2024. This FDA-approved rescue inhaler provides quick symptom relief combined with prompt anti-inflammatory effects, using an as-needed dual-mechanism dosage, real-time suppression of airway inflammation, and support in averting lung function deterioration linked to exacerbations. By enhancing asthma management, lowering the likelihood of severe attacks, and boosting overall rescue therapy performance, AIRSUPRA delivers significant clinical benefits.

Asthma Therapeutics Market Leading Players Shaping Industry Direction

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Access The Complete Asthma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Asthma Therapeutics Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Asthma Therapeutics Market?

The asthma therapeutics market has experienced significant growth in recent years. It is projected to increase from $33.11 billion in 2025 to $35.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. This historical growth can be linked to the limited availability of biologics, reliance on short-acting beta agonists, a rising global prevalence of asthma, an increase in hospital and specialty clinic visits, and the adoption of oral and inhaled medications.

The asthma therapeutics market size is projected to experience substantial expansion over the coming years. It is forecast to grow to $47.87 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. The expansion during the forecast period is primarily driven by the development of novel biologics and combination therapies, the increasing adoption of telemedicine and digital health monitoring, rising awareness of preventive treatments, improved healthcare access in emerging markets, and growing investment in research and drug development. Key trends in this period include the increasing uptake of personalized asthma therapies, greater usage of inhalers and biologics, the expansion of homecare and remote monitoring solutions, a growing preference for combination inhalers, and an enhanced focus on pediatric and geriatric asthma care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

What Important Drivers Are Powering The Asthma Therapeutics Market Growth?

The rising occurrence of asthma is anticipated to drive the expansion of the asthma therapeutics market in the future. Asthma is defined as a chronic condition characterized by inflammation and swelling in the airways, leading to their constriction, which impairs the flow of air from the nose and mouth to the lungs. This growing prevalence of asthma stems from an increase in pollutants, which provoke irritation in the airways and elevate the likelihood of developing the illness. Asthma therapeutics assist in managing the condition by regulating inflammation in the airways, alleviating symptoms, and averting asthma attacks. For example, in May 2025, the UK Parliament, a UK-based government body, reported that 3,886,879 individuals aged over six were diagnosed with asthma in 2023-24, making up 6.5% of England’s population. Consequently, the escalating occurrence of asthma is fueling the expansion of the asthma therapeutics market.

How Is The Asthma Therapeutics Market Distributed Across Key Segments?

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

Which Trends Are Guiding The Development Of The Asthma Therapeutics Market?

Leading companies within the asthma therapeutics market are concentrating on developing innovative solutions, such as anti-inflammatory rescue inhalers, to improve symptom relief, inflammation control, and overall disease management. An anti-inflammatory rescue inhaler is a dual-action therapeutic approach that combines a fast-acting bronchodilator with an inhaled corticosteroid in a single device, enabling rapid bronchodilation, on-demand inflammation reduction, and the prevention of severe asthma attacks. For instance, in January 2024, AstraZeneca plc, a UK-based biopharmaceutical company, introduced AIRSUPRA, an FDA-approved anti-inflammatory rescue inhaler specifically designed to provide immediate symptom alleviation along with swift anti-inflammatory action. It features as-needed dual-mechanism dosing, real-time suppression of airway inflammation, and support in averting exacerbation-related lung-function decline. AIRSUPRA enhances asthma control, diminishes the risk of severe attacks, and strengthens the overall effectiveness of rescue therapy.

Which Firms Are Competing In The Asthma Therapeutics Market?

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Access The Complete Asthma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

Which Region Stands As The Largest Contributor To The Asthma Therapeutics Market?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Asthma Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2026, By The Business Research Company

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Asthma Therapeutics Market Be By 2030 Compared To Its 2026 Market Size?

The asthma therapeutics market size has experienced significant expansion in recent years. It is projected to grow from $33.11 billion in 2025 to $35.73 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. This historical growth can be attributed to several factors including the limited availability of biologics, a reliance on short-acting beta agonists, the rising prevalence of asthma globally, an increase in hospital and specialty clinic visits, and the widespread adoption of oral and inhaled medications.

The asthma therapeutics market is projected to experience robust expansion over the coming years. This market is set to reach $47.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This anticipated growth throughout the forecast period stems from factors such as the creation of innovative biologics and combination treatments, the wider adoption of telemedicine and digital health monitoring, increasing awareness of preventive care, improved access to healthcare in developing economies, and increased investment in research and drug development. Key developments expected during this period involve the increasing embrace of personalized asthma treatments, a rise in the utilization of inhalers and biologic medications, the proliferation of homecare and remote monitoring systems, a growing preference for combination inhaler products, and an intensified focus on managing asthma in pediatric and geriatric populations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

What Significant Factors Are Influencing The Asthma Therapeutics Market Expansion?

The rising occurrence of asthma is projected to drive the expansion of the asthma therapeutics market in the future. Asthma is defined as a chronic condition characterized by inflammation and swelling of the air passages, leading to a constriction of the pathways that transport air from the nose and mouth to the lungs. This growing incidence of asthma can be attributed to a rise in pollutants, which irritate the respiratory tracts and elevate the likelihood of acquiring the condition. Asthma therapeutics assist in managing the condition by regulating inflammation in the airways, alleviating symptoms, and averting asthma attacks. For example, as reported by the UK Parliament, a UK-based government organization, in May 2025, a total of 3,886,879 individuals aged six and above were diagnosed with asthma during 2023-24, making up 6.5% of England’s population. Consequently, the growing frequency of asthma is fueling the development of the asthma therapeutics market.

Which Segment Classifications Are Used In The Asthma Therapeutics Market Segment Analysis?

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

What Trends Are Affecting The Direction Of The Asthma Therapeutics Market?

Leading firms in the asthma therapeutics sector are concentrating on creating novel solutions, including anti-inflammatory rescue inhalers, to improve symptom alleviation, manage inflammation, and advance comprehensive disease management. This type of rescue inhaler represents a dual-action therapy, merging a quick-acting bronchodilator with an inhaled corticosteroid within one device, thereby allowing for swift bronchodilation, immediate inflammation decrease, and the avoidance of acute asthma episodes. An example is AstraZeneca plc, a UK-based biopharmaceutical company, which introduced AIRSUPRA in January 2024. This FDA-approved anti-inflammatory rescue inhaler is engineered to provide instant symptom alleviation coupled with rapid anti-inflammatory effects, offering as-needed dual-mechanism dosing, real-time suppression of airway inflammation, and assistance in preventing the decline of lung function linked to exacerbations. AIRSUPRA contributes to better asthma management, lowers the likelihood of severe attacks, and enhances the overall efficacy of rescue therapies.

Which Firms Are Contributing To The Asthma Therapeutics Market Ecosystem?

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Get The Full Asthma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

Where Is The Asthma Therapeutics Market Primarily Concentrated By Region?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Asthma Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2026, By The Business Research Company

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Asthma Therapeutics Market Over The Period 2026–2030?

The asthma therapeutics market has shown substantial growth over recent years. It is anticipated to expand from $33.11 billion in 2025 to $35.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. This historical growth can be ascribed to several factors, including the limited availability of biologics, the reliance on short-acting beta agonists, the increasing global prevalence of asthma, a rise in hospital and specialty clinic visits, and the widespread adoption of oral and inhaled medications.

The asthma therapeutics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $47.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during this period can be ascribed to several factors, including the advancement of innovative biologics and combination treatments, the expansion of telemedicine and digital health monitoring, increasing awareness regarding preventive treatments, improved healthcare accessibility in developing markets, and escalating investment in research and drug development. Key trends expected within the forecast timeframe encompass the increasing embrace of personalized asthma therapies, a surge in the utilization of inhalers and biologics, the proliferation of homecare and remote monitoring options, an escalating preference for combination inhalers, and a heightened emphasis on asthma care for both pediatric and geriatric populations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

What Underlying Factors Are Accelerating The Growth Of The Asthma Therapeutics Market?

The rising occurrence of asthma is anticipated to drive the expansion of the asthma therapeutics market in the future. Asthma is a chronic illness characterized by inflammation and swelling in the airways, leading to their constriction, which impedes air transport from the nose and mouth to the lungs. This growing incidence of asthma is linked to an increase in pollutants, which irritate the airways and elevate the likelihood of developing the condition. Asthma treatments assist in managing the condition by regulating airway inflammation, alleviating symptoms, and averting asthma attacks. For example, as reported by the UK Parliament, a governmental body in the UK, in May 2025, approximately 3,886,879 individuals over six years old had been diagnosed with asthma in 2023-24, representing 6.5% of England’s population. Consequently, the rising occurrence of asthma is a key factor propelling the expansion of the asthma therapeutics market.

How Is The Asthma Therapeutics Market Divided Into Its Major Segments?

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

How Are Trends Transforming The Asthma Therapeutics Market Landscape?

Leading companies active in the asthma therapeutics market are prioritizing the development of inventive solutions, such as the anti-inflammatory rescue inhaler, to improve symptom alleviation, inflammation regulation, and holistic disease management. This particular type of inhaler represents a dual-action therapeutic strategy, integrating a fast-acting bronchodilator with an inhaled corticosteroid in a single device, thereby facilitating swift bronchodilation, immediate inflammation reduction, and the avoidance of severe asthma episodes. A notable instance occurred in January 2024, when AstraZeneca plc, a UK-based biopharmaceutical firm, unveiled AIRSUPRA, an FDA-approved anti-inflammatory rescue inhaler engineered to provide instant symptom relief concurrently with swift anti-inflammatory effects. It incorporates as-needed dual-mechanism dosing, offers real-time suppression of airway inflammation, and assists in averting lung-function deterioration linked to exacerbations. Ultimately, AIRSUPRA enhances asthma management, lessens the probability of severe attacks, and fortifies the overall efficacy of rescue therapy.

Who Are The Prominent Organizations Shaping The Asthma Therapeutics Market?

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Read the full asthma therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

Which Region Is Projected To Dominate The Asthma Therapeutics Market During The Forecast Period?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Asthma Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25702&type=smp

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2026, By The Business Research Company

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the asthma therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How much is the Asthma Therapeutics Market valued at in 2026, and what valuation is forecast for 2030?

The asthma therapeutics market size has seen significant expansion in recent years. This market is forecast to increase from $33.11 billion in 2025 to $35.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The growth observed in the past can be attributed to several factors, including the restricted access to biologics, a dependence on short-acting beta agonists, the increasing global incidence of asthma, a rise in visits to hospitals and specialty clinics, and the widespread adoption of oral and inhaled medications.

The asthma therapeutics market is projected to experience substantial expansion in the coming years, with its size forecast to reach $47.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is attributable to factors such as the development of innovative biologics and combination therapies, the broader adoption of telemedicine and digital health monitoring, heightened awareness of preventive treatments, improved healthcare accessibility in developing markets, and increased investment in research and drug development. Key trends anticipated over the forecast timeframe encompass the increasing integration of personalized asthma therapies, a surge in the utilization of inhalers and biologics, the proliferation of homecare and remote monitoring solutions, an escalating preference for combination inhalers, and a strengthened emphasis on asthma care for both pediatric and geriatric populations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

What Drivers Are Influencing The Growth Of The Asthma Therapeutics Market?

The escalating incidence of asthma is projected to fuel the expansion of the asthma therapeutics market in the future. Asthma is defined as a chronic condition characterized by inflammation and swelling within the airways, which leads to their constriction, thereby impeding air passage from the nose and mouth to the lungs. This rise in asthma prevalence stems from a growing presence of pollutants, known to irritate airways and elevate the likelihood of developing the disorder. Asthma therapeutics play a crucial role in managing the condition by regulating inflammation in the airways, alleviating symptoms, and averting asthma attacks. For illustration, data from May 2025, released by the UK Parliament, a government entity in the UK, revealed that 3,886,879 individuals aged six and above were diagnosed with asthma in 2023-24, representing 6.5% of England’s total population. Consequently, the heightened occurrence of asthma is a key factor propelling the expansion of the asthma therapeutics market.

How Is The Asthma Therapeutics Market Organized Into Various Segments?

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

What Trends Are Reshaping The Dynamics Of The Asthma Therapeutics Market?

Companies operating within the asthma therapeutics market are directing their efforts towards the creation of innovative solutions, such as the anti-inflammatory rescue inhaler, aiming to improve symptom alleviation, inflammation regulation, and general disease management. The anti-inflammatory rescue inhaler functions as a dual-action therapeutic method, integrating a quick-acting bronchodilator with an inhaled corticosteroid within a single inhaler, thereby facilitating capabilities such as swift bronchodilation, immediate inflammation reduction, and the avoidance of severe asthma episodes. For example, in January 2024, AstraZeneca plc, a UK-based biopharmaceutical company, launched AIRSUPRA, an FDA-approved anti-inflammatory rescue inhaler engineered to deliver instant symptom relief alongside rapid anti-inflammatory action, offering as-needed dual-mechanism dosing, real-time suppression of airway inflammation, and support in preventing lung-function decline associated with exacerbations. AIRSUPRA contributes to better asthma control, decreases the likelihood of severe attacks, and strengthens the overall efficacy of rescue therapy.

Who Are The Core Companies Influencing Trends In The Asthma Therapeutics Market?

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

Which Regions Are Projected To Dominate The Asthma Therapeutics Market In The Coming Years?

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Asthma Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25702&type=smp

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2026, By The Business Research Company

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model